Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservat
Go back to Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservat| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.58 +0.04 (1.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.54 | 52 Week High | $8.30 | |||
| Open | $2.50 | 52 Week Low | $2.43 | |||
| Day High | $2.67 | P/E | N/A | |||
| Day Low | $2.49 | EPS | $-0.22 | |||
| Volume | 780,950 | |||||
| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.58 +0.04 (1.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.54 | 52 Week High | $8.30 | |||
| Open | $2.50 | 52 Week Low | $2.43 | |||
| Day High | $2.67 | P/E | N/A | |||
| Day Low | $2.49 | EPS | $-0.22 | |||
| Volume | 780,950 | |||||
